Centricity Wealth Management LLC Purchases New Holdings in Novo Nordisk A/S (NYSE:NVO)

Centricity Wealth Management LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,068 shares of the company’s stock, valued at approximately $178,000.

A number of other institutional investors and hedge funds have also modified their holdings of NVO. WCM Investment Management LLC increased its holdings in Novo Nordisk A/S by 1.0% in the 4th quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock valued at $345,588,000 after buying an additional 40,475 shares during the period. Natixis Advisors LLC increased its stake in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the period. DSM Capital Partners LLC raised its position in Novo Nordisk A/S by 16.7% in the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after purchasing an additional 286,912 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. Finally, LPL Financial LLC boosted its holdings in Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE:NVO opened at $83.79 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $376.02 billion, a P/E ratio of 25.47, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The company’s 50-day moving average price is $86.39 and its two-hundred day moving average price is $108.48.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.